Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Antigen pressure from two founder viruses induces multiple insertions at a single antibody position to generate broadly neutralizing HIV antibodies

PROVIDER: PRJNA943240 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR24052920_subreads.fastq.gz	Fastqsanger.gz
	SRR24052921_subreads.fastq.gz	Fastqsanger.gz
	SRR24052922_subreads.fastq.gz	Fastqsanger.gz
	SRR24052923_subreads.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 294

Similar Datasets

Prediction of broadly neutralizing antibodies

Project description:Prediction of broadly neutralizing antibodies

| PRJNA952996 | ENA

Prediction of broadly neutralizing antibodies [Singleron]

Project description:Prediction of broadly neutralizing antibodies [Singleron]

| PRJNA952999 | ENA

Prediction of broadly neutralizing antibodies [10X]

Project description:Prediction of broadly neutralizing antibodies [10X]

| PRJNA952157 | ENA

Prediction of broadly neutralizing antibodies [BD Rhapsody]

Project description:Prediction of broadly neutralizing antibodies [BD Rhapsody]

| PRJNA952998 | ENA

CHIKV VLP Vaccination in Humans induced broadly neutralizing antibodies

Project description:CHIKV VLP Vaccination in Humans induced broadly neutralizing antibodies

| PRJNA905836 | ENA

Overcoming steric restrictions of VRC01 HIV-1 neutralizing antibodies through immunization

Project description:Broadly HIV-1 neutralizing VRC01-class antibodies target the CD4-binding site of Env. They are derived from VH1-2*02 antibody heavy chains paired with rare light chains expressing five amino acid long CDRL3s. They have been isolated from infected subjects but have not yet been elicited by immunization. Env-derived immunogens capable of binding the germline forms of VRC01 B cell receptors on naïve B cells have been designed and evaluated in knock-in mice. However, the elicited antibodies cannot bypass glycans present on the conserved position N276 of Env, which restricts access to the CD4-binding site. Efforts to guide the appropriate maturation of these antibodies by sequential immunization have not yet been successful. Here, we report on a two-step immunization scheme that led to the maturation of VRC01-like antibodies capable of accommodating the N276 glycan and displaying autologous tier 2 neutralizing activities. Our results are relevant to clinical trials aiming to elicit VRC01 antibodies.

2020-05-26 | PXD015168 | Pride

Project description:B cell clonal lineage containing broadly neutralizing anti-neuraminidase antibodies

| PRJNA630537 | ENA

Macrophages direct location-dependent recall of B cell memory to vaccination [scRNA-seq and scVDJ-seq]

Project description:Vaccines generate long-lived plasma cells and memory B cells (Bmems) that may re-enter secondary germinal centers (GCs) to further mutate their B cell receptor upon boosting and re-exposure to antigen. We show that lymph nodes draining the primary vaccination site harbour a subset of Bmems that reside in the subcapsular niche, generate larger recall responses, and are more likely to re-enter GCs compared to circulating Bmems in non-draining lymph nodes. Depletion of CD169+ subcapsular sinus macrophages impairs Bmem proliferative expansion, secondary GC formation and secretion of affinity-matured antibodies upon boosting of the draining lymph node. This site-specific, niche-dependent control is associated with more rapid secretion of broadly neutralizing antibodies, GC participation and clonal expansion of SARS-CoV-2-specific B cells in healthy volunteers boosted with the BNT162b2 vaccine in the same versus opposite arm. These data reveal an unappreciated role for primed draining lymph node SSMs in Bmem cell fate determination.

2025-06-30 | GSE291745 | GEO

Macrophages direct location-dependent recall of B cell memory to vaccination [CITE-seq]

2025-06-30 | GSE291315 | GEO

Homo sapiens

Project description:Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

| PRJNA202933 | ENA